Literature DB >> 23201853

Correlates of protection following vaccination of mice with gene deletion mutants of Francisella tularensis subspecies tularensis strain, SCHU S4 that elicit varying degrees of immunity to systemic and respiratory challenge with wild-type bacteria.

Patrik Ryden1, Susan Twine, Hua Shen, Gregory Harris, Wangxue Chen, Anders Sjostedt, Wayne Conlan.   

Abstract

Francisella tularensis subspecies tularensis is an extremely virulent facultative intracellular bacterial pathogen capable of causing significant mortality in humans when inhaled. Consequently, subspecies tularensis was developed as a biological weapon more than 50 years ago. To counter this threat the US Army empirically developed a live vaccine strain, F. tularensis LVS, from the less virulent holarctica subspecies. In human experiments LVS afforded substantial protection against transdermal challenge with clinical subspecies tularensis strain, SCHU S4, but lesser protection against infection initiated by inhalation of the pathogen. Several regulatory and clinical issues remain unresolved for this vaccine, including the absence of a robust correlate of protection. To try to address this, we have developed several defined gene deletion mutants of SCHU S4 that elicit varying degrees of protection in a mouse dermal or respiratory challenge model. In the present study, we have examined whether host immune responses to immunization with such live vaccine candidates can serve as correlates of protection. Antibody responses were unable to distinguish between effective and ineffective vaccine strains. However, several cytokine responses to vaccination showed some promise. Especially, serum levels of TNFα, IFNγ, and MCP-1 between days 4 and 7 after vaccination appear to correlate with protection against respiratory challenge. Crown
Copyright © 2012. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23201853     DOI: 10.1016/j.molimm.2012.10.043

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  23 in total

1.  Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cells.

Authors:  Giang H Pham; Bibiana V Iglesias; Edmund J Gosselin
Journal:  Vaccine       Date:  2014-07-26       Impact factor: 3.641

2.  Identification of mechanisms for attenuation of the FSC043 mutant of Francisella tularensis SCHU S4.

Authors:  Marie Lindgren; Linda Tancred; Igor Golovliov; Wayne Conlan; Susan M Twine; Anders Sjöstedt
Journal:  Infect Immun       Date:  2014-06-16       Impact factor: 3.441

3.  Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

Authors:  Katharina Richard; Barbara J Mann; Lenea Stocker; Eileen M Barry; Aiping Qin; Leah E Cole; Matthew T Hurley; Robert K Ernst; Suzanne M Michalek; Daniel C Stein; Philip Deshong; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

4.  Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain.

Authors:  Douglas S Reed; Le'kneitah P Smith; Kelly Stefano Cole; Araceli E Santiago; Barbara J Mann; Eileen M Barry
Journal:  Infect Immun       Date:  2014-03-10       Impact factor: 3.441

5.  Next Generation Vaccine Biomarkers workshop October 30-31, 2014--Ottawa, Canada.

Authors:  Susan M Twine; Kelly M Fulton; John Spika; Marc Ouellette; Jennifer F Raven; J Wayne Conlan; Lakshmi Krishnan; Luis Barreto; James C Richards
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Francisella tularensis type B ΔdsbA mutant protects against type A strain and induces strong inflammatory cytokine and Th1-like antibody response in vivo.

Authors:  Adela Straskova; Petra Spidlova; Sherry Mou; Patricia Worsham; Daniela Putzova; Ivona Pavkova; Jiri Stulik
Journal:  Pathog Dis       Date:  2015-08-06       Impact factor: 3.166

Review 7.  Live attenuated tularemia vaccines: recent developments and future goals.

Authors:  Mark E Marohn; Eileen M Barry
Journal:  Vaccine       Date:  2013-06-10       Impact factor: 3.641

8.  High-Quality Draft Genome Sequence of Francisella tularensis subsp. holarctica Strain OR96-0246.

Authors:  L M Atkins; M E Holder; N J Ajami; G A Metcalf; G M Weissenberger; M Wang; V Vee; Y Han; D M Muzny; R A Gibbs; J F Petrosino
Journal:  Genome Announc       Date:  2015-08-13

9.  Preclinical testing of a vaccine candidate against tularemia.

Authors:  Ragavan Varadharajan Suresh; Zhuo Ma; Raju Sunagar; Vivek Bhatty; Sukalyani Banik; Sally V Catlett; Edmund J Gosselin; Meenakshi Malik; Chandra Shekhar Bakshi
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

10.  A ΔclpB mutant of Francisella tularensis subspecies holarctica strain, FSC200, is a more effective live vaccine than F. tularensis LVS in a mouse respiratory challenge model of tularemia.

Authors:  Igor Golovliov; Susan M Twine; Hua Shen; Anders Sjostedt; Wayne Conlan
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.